glp-1 medicaid California Ends Coverage of Weight Loss Drugs Despite TrumpRx Plan CMS Expands Access to GLP-1

#Pharmacology #ClinicalPharmacology #DrugDiscovery #PharmaResearch #ObesityTreatment #HealthcareInnovation #DrugSafety

But another conversation has begun gaining momentum centered on fiber and the gut microbiome.

David Shafer explains why volume loss appears, what helps, and when fillers may work.

When fiber reaches the colon, beneficial gut bacteria ferment it into short-chain fatty acids (SCFAs), which stimulate the release of GLP-1

Lipedema, a chronic fat condition that mostly affects women, is characterized by an abnormal accumulation of fat in the hips, thighs, and arms.

GLP-1 agonists like semaglutide and tirzepatide are groundbreaking for weight loss